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ABSTRACT
Platelet derived growth factor (PDGF) regulates
gene transcription by binding to specific receptors.
PDGF plays a critical role in oncogenesis in brain
and other tumors, regulates angiogenesis, and
remodels the stroma in physiologic conditions.
Here, we show by using microRNA (miR) arrays
that PDGFs regulate the expression and function
of miRs in glioblastoma and ovarian cancer cells.
The two PDGF ligands AA and BB affect expression
of several miRs in ligand-specific manner; the most
robust changes consisting of let-7d repression by
PDGF-AA and miR-146b induction by PDGF-BB.
Induction of miR-146b by PDGF-BB is modulated
via MAPK-dependent induction of c-fos. We demon-
strate that PDGF regulates expression of some of its
known targets (e.g. cyclin D1) through miR alter-
ations and identify the epidermal growth factor
receptor (EGFR) as a new PDGF-BB target. We
show that its expression and function are repressed
by PDGF-induced miR-146b and that mir-146b and
EGFR correlate inversely in human glioblastomas.
We propose that PDGF-regulated gene transcription
involves alterations in non-coding RNAs and provide
evidence for a miR-dependent feedback mechanism
balancing growth factor receptor signaling in cancer
cells.
INTRODUCTION
Two structurally similar receptor tyrosine kinases are
activated by the platelet derived growth factor, PDGF
(1,2). PDGF induces cell growth and survival (3), trans-
formation (4), migration, vascular permeability and
wound healing (5). PDGF is a dimeric molecule
composed of two disulﬁde-bound chains (A and B) (6).
It binds selectively to receptor subunits, based on
speciﬁc epitopes (7), PDGF-AA binding PDGFR-a,
PDGF-AB and -BB recognizing both PDGFR-a and
PDGFR-b subunits (2). Two recently cloned PDGF
chains (C and D) (8,9) bind the PDGFR-a and
PDGFR-b, respectively. PDGFR activation occurs
through dimerization and autophosphorylation of
tyrosine residues in the intracellular domain (10). The
two PDGFRs mediate similar, but not identical processes,
PDGFR-b being more efﬁcient in mediating chemotactic
effects (11), transformation (12) and intracellular Ca
+ +
trafﬁc (13).
Experimental studies have implicated aberrant PDGFR
signaling in oncogenesis, particularly in glioblastomas
(GBM) (14), sarcomas (15) and selected epithelial
cancers [breast and ovarian cancer (16,17)]. PDGFR acti-
vation in cancer occurs as a consequence of gene ampliﬁ-
cation [GBMs (14)], chromosomal rearrangements (18) or
activating mutations (19). Activation of PDGFR in
tumors can also occur through autocrine or paracrine
stimulation (20–23) as both tumor and normal cells in
the stroma secrete PDGF. Work in our laboratory
demonstrated that PDGFR and its ligands are expressed
in ovarian tumors, PDGF is detectable in malignant
ascites, and the PDGFR is activated by tumor
cell-secreted ligand (24). Autocrine PDGFR activation
was also described in brain tumors as an important step
to tumor progression (21,25). PDGF signaling in neural
stem cells was linked to tumor initiation (26) and auto-
crine PDGF stimulation of de-differentiated astrocytes
induced gliomagenesis (21,23). Autocrine activation of
the receptor may contribute to adverse clinical outcome
in ovarian (16) and other tumors (22,27,28). PDGFR
stimulation leads to activation of intracellular signaling,
particularly of Akt, Src and ras/MAPK1/2, with
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(17,24,29). The mechanisms accounting for differences
between effects elicited by distinct PDGF ligands are not
well understood, having been previously attributed to
cell-speciﬁc contexts.
MicroRNAs (miR) are single stranded 16–24nt regula-
tory RNAs that repress target gene expression by inhibit-
ing translation or by promoting target mRNA
degradation. Emerging evidence implicates miRs in
human cancer, where they act either as oncogenic
factors (through repression of tumor suppressor genes)
or as tumor suppressors (30,31). As each miR targets
multiple genes, it is predicted that  30–40% of genes
deregulated in human cancer are under the control of
cancer-associated microRNAs (32). Through their effects
on gene expression in cancer cells, miRs regulate key
cellular mechanisms such as cell differentiation, survival,
proliferation and metabolism (33). miR dysregulation in
tumor cells may occur constitutively (through deletion,
ampliﬁcation of chromosomal fragments or mutations)
(34) or as consequence of micro-environmental factors
(e.g. hypoxia, cytokines, estrogens) (35–37). The goal of
this study was to identify miRs regulated by PDGFs and
their functions in cancer cells.
Here we identify non-coding RNAs (ncRNAs) speciﬁc-
ally regulated by each of the two PDGF ligands, AA and
BB. We show that PDGF-BB, but not AA, induces
miR-146b expression through a Fos-dependent mechanism
and that in turn, this miR regulates the expression of
the epidermal growth factor receptor, the EGFR.
We provide evidence that a ncRNA modulates the
balance between two growth factor receptor pathways in
cancer cells (PDGFR and EGFR), suggesting the exist-
ence of a feedback loop that allows cancer cells to use
one pathway selectively over the other. We propose that
alterations in miR expression represent one potential
mechanism by which PDGFs regulate target gene expres-
sion (e.g. cyclin D1 and EGFR). Other miRs induced or
repressed by PDGFs and their effects on gene transcrip-
tion are identiﬁed and discussed.
MATERIALS AND METHODS
Materials and cell lines
PDGF BB, PD98059 and LY294002 were from Sigma
(St Louis, MO, USA), PDGF AA from PeproTech
(Rocky Hill, NJ, USA) and EGF and VEGF from R&D
(Minneapolis, MN). All cells were treated with PDGF BB
and AA at 25ng/ml unless otherwise speciﬁed and with
EGF at 20 and 150ng/ml. U118-MG, U87-MG glioblast-
oma cells, and human WI-38 ﬁbroblasts (ATCC,
Manassas, VA, USA) were grown according to ATCC
instructions. The immortalized ovarian cells C272/hTert/
E7 were previously described (38) and grown in a 1:1
mixture of MCDB 105 (Sigma) and M199 media
(Cellgro, Herndon, VA, USA) supplemented with FBS.
Neuroblastoma cells SHSY-5Y were from Dr Carol
Thiele of the National Cancer Institute (39). Nineteen
de-identiﬁed snap-frozen human glioblastoma specimens
were acquired from the Indiana University Cancer Center
Tissue Bank and from the Brain Tumor Tissue Bank
(BTTB) of London Health Sciences Centre (London,
ON, Canada). Their use was approved by the
Institutional Review Board.
MicroRNA microarrays and statistical analysis
RNA extracted from cells stimulated with PDGF or
control was biotin labeled and hybridized to custom
made microRNA chips containing 900 probes for human
mature and precursor miRs; 700 probes four mouse miRs,
900 probes for ultraconserved sequences and controls
(array express accession, A-MEXP-1246). All probes on
the array were duplicated, and average values were used
for the analysis. Two biological replicates for each
time-point (0, 2, 6, 12 and 24 h) were analyzed. Data
were normalized using quantiles algorithm (www
.bioconductor.org). Absent calls were assigned at a thresh-
old of 4.5 (log2) before statistical analysis. miR probeswere
excluded from analysis if <20% of expression data values
had at least a 1.5-fold change in either direction from the
miR median value. Two-sample t-test (with random
variance model) utilizing the Biometric Research Branch
(BRB) array tool version 3.6.0 (https://linus.nci.nih.gov/
BRB-ArrayTools.html) was used to perform the class com-
parison between unstimulated and PDGF-stimulated
samples or between PDGF-AA and PDGF-BB treated
samples. miRs signiﬁcant at the 0.01 level (two-sided) of
the univariate test are reported. Hierarchical clustering was
performed by using the expression of the differentially
regulated miRs across experiments. The mean was
computed over all samples from the same class. MiRs
and arrays were mean-centered and normalized by using
GENE CLUSTER 3.0. Average linkage clustering was
performed by using Euclidean distance and displayed
using TreeView program (http://rana.lbl.gov/
EisenSoftware.htm). Clustering trees display average ex-
pression values after log2 transformation. Principal com-
ponent analysis (PCA) used unsupervised and supervised
classiﬁcation algorithms from Partek Genomics Suite
(http://www.partek.com/) of normalized and ﬁltered data.
Immunoblotting
Actively growing cells were lysed into RIPA buffer
containing leupeptin (1mg/ml), aprotinin (1mg/ml),
PMSF (400mM) and Na3VO4 (1mM). Cell lysates were
sonicated and incubated on ice for 30min. Cellular
debris was removed by centrifugation for 15min. Equal
amounts of protein were fractionated by SDS–PAGE,
transferred to a nitrocellulose membrane and treated
with primary antibodies against phospho-PDGFRa
(Santa Cruz, sc-12911-R), PDGFRa (Cell Signaling,
#3164), phospho-PDGFRb (Cell Signaling, #3166S),
PDGFRb (Santa Cruz, sc-339), phospho-AKT (Cell
Signaling, #4060X), phospho-MAPK-P42/44 (Cell
Signaling, #9101S), phospho-EGFR (Cell Signaling,
#2236S), EGFR (Santa Cruz, sc-03), c-fos (Santa Cruz,
sc-52), cyclin D1 (Cell Signaling, #2922) and GAPDH
(Santa Cruz) during an overnight incubation at 4 C.
After incubation with corresponding HRP-labeled second-
ary antibodies, enhanced chemiluminescence was used
4036 Nucleic Acids Research, 2011,Vol.39, No. 10for protein visualization. Western blots were repeated in
independent conditions at least twice.
Quantitative real-time reverse transcription–PCR
Mature miR expression was quantiﬁed by qPCR from
total RNA extracted from cell cultures or tumors with
RNA STAT-60 reagent (Tel-Test Inc.). Total RNA
(200–500ng) was reverse transcribed with TaqMan
MicroRNA Reverse Transcription Kit (Applied
Biosystems). miR expression levels were quantiﬁed by
using probes from TaqMan MicroRNA Assays
(Applied Biosystems) on an ABI Prism 7900 platform
(Applied Biosystems) according to the manufacturer’s
protocol. At the end of the PCR reaction a melting
curve was generated and the cycle threshold (Ct) was
recorded. Relative expression of microRNA of interest
was calculated as Ct, measured by subtracting the
Ct of the reference microRNA from that of the RNU49
control (for cancer cell lines) and snRNA U6 (for human
glioblastoma samples). qPCR for EGFR used the
FastStart Taqman Probe Master (Roche) and results
were normalized to GAPDH. Primers are included in
Supplementary Table S1. Results are presented as
means±standard deviation (SD) of replicates. Each
measurement was performed in duplicate and repeated.
Student’s t-test compared mean miR expression levels
between groups and Pearson coefﬁcient measured the
correlation between EGFR and miR-146b.AP<0.05
was deemed signiﬁcant.
Transfection
To knockdown let-7d and miR-146b, we used locked
nucleic acids (LNA) MiRCURY LNA
TM and scrambled
LNA from Exiqon (Denmark). To overexpress let-7d and
miR-146b, we used pre-miR
TM miRNA Precursor
and negative control #1 from Ambion (Austin, TX,
USA). Transfection was facilitated by Dreamfect (Oz
Biosciences) according to manufacturer’s instructions.
SiRNA against c-fos and scrambled siRNA (control)
were purchased from Dharmacon (Lafayette, CO, USA).
Typically miR or gene knock-down or overexpression
were achieved within 24–48h of transfection. After trans-
fection and/or treatments, cells were harvested for RNA
or protein analyses at speciﬁed time-points.
Reporter assay
A Dual-Luciferase Assay (Promega) was performed
to quantify EGFR 30-UTR activities. EGFR 30-UTR
reporter clone pMirTarget-EGFR was from Origene
(SC216236). The predicted miR-146b target site between
1064 and 1085bp was deleted by using the QuickChange
II Site-directied Mutagenesis Kit (Agilent Technologies
#200523-5) to generate the pMirTarget-Mut clone and
veriﬁed by sequencing. U118 cells were co-transfected
with pMirTarget-EGFR or pMirTarget-Mut and
control reporter plasmid (renilla) at a ratio of 10:1 by
using FuGENE HD transfection Reagent (Roche).
Luminescence was measured by using a TD-20/20
luminometer (Turner Biosystems). Experiments were
performed in triplicate and repeated in independent
conditions two times. To control for transfection
efﬁciency, values for luminescence were normalized to
renilla activity.
BrdU assay
An ELISA based assay (Roche Applied Science) measured
cell proliferation of C272-hTert/E7 cells transfected
with let-7d precursor and control and stimulated with
PDGF-AA, according to manufacturer’s instructions.
Chromatin immunoprecipitation
To detect the interaction between c-fos and the miR-146b
promoter, we used chromatin immunoprecipitation
(ChiP). In brief, C272-hTert/E7 cells were treated with
PDGF-BB for 3 h, then ﬁxed in 1% formaldehyde, lysed
into 0.01% SDS, 1.1% Triton X-100, 1.2mM EDTA,
16.7mM Tris–HCl (pH 8.1), 167mM NaCl and sonicated.
The soluble chromatin was pre-cleared by incubation with
sheared salmon sperm DNA–protein. One portion of
the supernatant was used as a DNA input control,
and the remainder was incubated with rabbit IgG or
a Fos antibody (overnight, 4 C). Immunoprecipitated
complexes were incubated with protein A slurry, washed
successively with low-salt buffer [0.1% SDS, 1% Triton
X-100, 2mM EDTA, 20mM Tris–HCl (pH 8.1), 150mM
NaCl], high-salt buffer (500mM NaCl), LiCl buffer
[0.25M LiCl, 1% IGEPAL-CA630, 1% deoxycholate,
1mM EDTA, 10mM Tris–HCl (pH 8.1)] and
Tris–EDTA (pH 8.0), and then eluted with 1% SDS,
100mM NaHCO3 buffer. Cross-linking of protein–DNA
complexes was reversed by incubation with 5M NaCl at
65 C for 4 h, and DNA was digested with 10mg/ml
of proteinase K (1 h, 45 C). The DNA was extracted
with phenol–chloroform and subjected to PCR ampliﬁca-
tion using primers designed for the predicted c-fos binding
domain in the miR-146b promoter: CAGTGGCTCACAC
CTGTAATTC (f) and GTAGCACAATCACGGCTT
ACTG (r). The 242-bp PCR products were resolved
by 2% agarose–ethidium bromide gel electrophoresis,
visualized by UV and analyzed with the Kodak gel
analysis system. As another negative control, DNA
immunoprecipitated with c-fos antibody was ampliﬁed
with primers designed for a fragment located 1000bp
downstream of miR-146b (F: 50-GCCTACCAAAGTGC
TGGGATTAC-30 and R: 50-ATATGCTGGACGCTGG
ACTAGAC-30).
Statistical analysis
The Student’s t-test compared quantitative data between
groups; P<0.05 being signiﬁcant.
RESULTS
MiRNAs regulated by PDGF
We hypothesized that the response to PDGF involves
alterations in miR expression and employed miR micro-
arrays to identify such changes. U118 glioblastoma cells
expressing both subunits of the PDGFR, a and b, were
treated with PDGF-AA or PDGF-BB over a 24h
Nucleic Acids Research, 2011,Vol.39, No. 10 4037time-course. RNA extracted at 0, 2, 6, 16 and 24h was
used for miR expression proﬁling. A two-sample t-test
with random variance was used to perform the class com-
parison between un-stimulated and PDGF-stimulated
samples and miRs signiﬁcant at the P<0.01 level of the
univariate test are reported. Twenty miRs were induced or
repressed by PDGF, with 7 being altered by PDGFAA
(four up-regulated and three down-regulated) and 13
affected by PDGF BB (11 up-regulated and two
down-regulated). Tables 1 and 2 summarize miRs whose
expression is altered by PDGFs compared to
un-stimulated cells. Surprisingly no miR was altered in
a similar manner by both PDGF-AA and PDGF-BB at
P<0.01. Comparison of miR proﬁles combining all
time-points after PDGF-AA or PDGF-BB stimulation
revealed two miRs (let-7g and miR-556) most differential-
ly altered by the two PDGFs (P<0.01, Supplementary
Table S1).
Cluster analysis shows global differences between miRs
altered by PDGF-AA and PDGF-BB, let-7d being one of
the miRs repressed by PDGF-AA (Figure 1A) and
mir-146b being one of the miRs induced by PDGF-BB
(Figure 1B). These two miRs were studied in further
detail in subsequent analyses. Supervised and
unsupervised PCA miR classiﬁcation was performed for
samples stimulated with PDGF-AA or PDGF-BB at
different timepoints versus un-stimulated samples.
Analyses summarized in Supplementary Figure S1A and
B demonstrate signiﬁcant differences in miR expression
patterns induced by the two PDGFs versus un-stimulated
cells. Likewise PCA was used to classify miRs altered
by PDGF-AA versus PDGF-BB (Supplementary
Figure S1C–F) demonstrating discriminatory miR
proﬁles elicited by the two PDGF ligands. Selected miRs
emerging from the microarray analysis were conﬁrmed by
qPCR. The U118MG, C272/hTert/E7 and WI38 cells
express both PDGF receptor subunits, while U87MG
cells express predominantly PDGFR-b (Supplementary
Figure S2A). Supplementary Figure S2 includes selected
validation studies conﬁrming by qPCR miR alterations
induced by PDGF, such as miR-106b up-regulation by
PDGF-BB.
PDGF-AA represses let-7d in cancer cells
Further conﬁrmation of the microarray generated data
focused on let-7d as a speciﬁc target of PDGF-AA and
on miR-146b as a PDGF-BB inducible miR. Up to 50%
let-7d repression by PDGF-AA was evident U118MG,
Table 2. Speciﬁc PDGF BB inducible or repressible microRNAs
miR Chromosome Fold-changes P-value Expression in cancer Function
miR-106b 7q22.1 4.6 0.0433 Up in prostate cancer Suppresses E2F1 and p21
miR-30b 8q24  9.2 0.005 Down in cancer stem cells Self renewal and survival of cancer stem
cells
miR-30c 1p34  5.6 1.16E 05 Down in cancer stem cells Self renewal and survival of cancer stem
cells
miR-146b 10q24.32 9.3 1.96E 05 Up in thyroid, breast, pancreatic cancer Suppresses KIT
Inducible by TNF
miR-198 3q13 3.2 0.003 Down in hepatocellular carcinoma up in
prostate cancer
Not known
miR-181a1 1q31.32 6.2 0.006 Up in pancreatic, thyroid and colon
cancer
Target of p53
miR-631 15.q24 4.7 0.0006 Not known Not known
miR-1 18q11 3.1 0.004 Up in prostate cancer, down-regulated
in other cancers
Suppresses E2F1
Synaptic signaling
miR-613 12p13 3.4 0.004 Not known Not known
miR-129-1 7q32.1 5.3 0.039 Up in retinoblastoma, down-regulated
in other cancers
Not known
miR-216 2p18.1 2.9 0.0017 Down-regulated in pancreatic cancer Not known
miR-499 20q11.22 3.7 0.0062 Not know Expressed in myocytes, involved in cell
senescence
miR-564 3p21.31 9.4 1.84E 05 Not known Not known
Table 1. Speciﬁc PDGF AA inducible or repressible microRNAs
miR Chromosome Fold-changes P-value Expression in cancer Function
mir-126-5p 9q24  19.1 4.54E–05 Lost in breast cancer Suppresses cell proliferation
miR-149 2q37 4.8 0.0003 Down in glioblastoma, melanoma Not known
miR-185 22q11.21 3.9 0.0089 Up in hepatocellular and bladder cancer Not known
miR-663 20p11.21 5.5 0.0011 Up in ovarian, lost in breast cancer Epigenetic silencing in breast cancer
miR-769-5p 19q13.33 5.2 0.0087 Not known Not known
Let-7d 9q22  9.5 0.0048 Down in hepatocellular, ovarian, lung cancer Suppresses cell proliferation
miR-770P 14q42  6.0 0.002 Not known Not known
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PDGF-AA stimulation. The effect of PDGF-AA on
let-7d occurred rapidly (2–6h, Figure 1C–F), although
some variability in the kinetic response of let-7d to
PDGF-AA was evident in the different cell lines tested.
For instance in C272/hTert/E7 cells the repression of
let-7d persisted for 24h, whereas in U118MG cells the
level of let-7d returned to normal 24h after PDGF-AA
stimulation. While some of the PDGFR-expressing
cancer cells tested here secrete PDGF, the
neuroblastoma cells SH-SY5Y cells express both PDGF
receptors but do not secrete PDGFs (40). Thus the effects
of PDGF-AA on let-7d expression are independent of
autocrine secretion of this growth factor (Figure 1E).
Figure 1. Hierarchical clustering demonstrates speciﬁc effects of PDGF-AA and PDGF–BB on miR expression in U118 cells. (A) Differential
expression of miRs is induced by PDGF-AA and PDGF-BB at different timepoints. Among other miRs, let-7d is suppressed by PDGF-AA
(see arrow). (B) Effects of PDGF-BB on miR expression (0 versus 12h). Among other miRs, miR-146b is induced by PDGF-BB (see arrow).
qPCR quantiﬁes let-7d expression levels in U118 MG (C), C272/hTert/E7 (D), SH-SY5Y (E) and WI38 cells (F) after PDGF-AA treatment.
Statistical signiﬁcance is marked by asterisks.
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growth factors, let-7d expression was quantiﬁed in
C272hTert/E7 cells treated with PDGF-AA, PDGF-BB,
EGF and VEGF. A  40% decrease in Let-7d level was
observed in response to PDGF-AA, with no measurable
changes observed in PDGF-BB, EGF or VEGF-treated
cells (Figure 2A).
To test the functional signiﬁcance of let-7d repression
by PDGF-AA, we measured its effects on one of its best
documented targets, cyclin D1 (33). Cyclin D1 is induced
Figure 2. PDGF-AA down-regulates let-7d expression. (A) qPCR quantiﬁes let-7d expression in C272/hTert/E7 cells in response to PDGF-AA,
PDGF-BB, VEGF and EGF. RNU49 was used as control. (B) Western blotting for cyclin-D1 in C272/hTert/E7 cells treated with PDGF-AA.
(C) Western blotting for cyclin D1 in U118MG cells transfected with let-7d precursor or control (left panel). Western blotting for cyclin D1 in
U118MG cells transfected with LNA targeting let-7d or scrambled LNA (right panel). (D) Western blotting assessed cyclin D1 in C272/hTERT/E7
cells treated with PDGF-AA for 6h after transfection of let-7d precursor or control (left panel). Densitometry quantiﬁes cyclin D1 expression levels
relative to GAPDH in independent experiments. Statistical signiﬁcance is indicated by asterisks (NS, not signiﬁcant). (E) BRDU assay quantiﬁes cell
proliferation of C272/hTert/E7 cells transfected with let-7d precursor and control and stimulated with PDGF-AA or vehicle Statistical signiﬁcance is
marked by asterisks.
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to be implicated in PDGF-stimulated cell proliferation
(41). To test its role in the context of PDGF-regulated
miR alterations, Let-7d was overexpressed and knocked
down and cyclin D1 expression levels were measured.
Overexpression in U118MG cells was achieved by trans-
fection of the let-7d pre-miR and conﬁrmed by qPCR
(not shown). Overexpression of let-7d repressed cyclin
D1 expression (Figure 2C, left panel). Likewise let-7d
knockdown was achieved by transient transfection of an
LNA targeting this miR and conﬁrmed by qPCR
(not shown). Let-7d knockdown induced cyclin D1
(Figure 2C, left panel). To show that repression of let-7d
by PDGF-AA was signiﬁcant to the regulation of cyclin
D1 by PDGF, this miR was overexpressed. Subsequent
treatment with PDGF-AA in cells overexpressing let-7d
did not signiﬁcantly affect cyclin D1 expression
(P=0.3) as compared to the effect of PDGF-AA on
cyclin-D1 in cells transfected with a control sequence
(P=0.02, Figure 2D). Further, this effect was implicated
in PDGF-AA-induced cell proliferation, as let-7d
overexpression inhibited PDGF-AA induced BRDU
incorporation in proliferating cells (Figure 2E,
P=0.03). Collectively, these data indicate that
PDGF-AA regulates critical cell cycle components and
S-phase entry in part via down-regulation of let-7d.
PDGF-BB induces miR-146b in cancer cells
Next, we focused on the effects of PDGF-BB and showed
by qPCR that miR-146b was induced by up to 2-fold in
U118MG, U87MG, C272hTert/E7 and SH-SY5Y cells
within 6–16h (Figure 3A). The induction in miR-146b
expression was sustained (up to 24h) in the cancer cells
tested here. Lesser induction of miR-146b ( 30%) was
observed in non-transformed WI38 ﬁbroblasts stimulated
with PDGF-BB (Figure 3B). To test the speciﬁcity of this
miR’s response to individual growth factors, C272/hTert/
E7 cells were treated with PDGF-AA, PDGF-BB, EGF
and VEGF and miR-146b was quantiﬁed. A 2-fold
increase in miR-146b expression level was noted in
response to PDGF-BB, while PDGF-AA, EGF and
VEGF did not induce signiﬁcant variation of miR-146b
levels (Figure 3C).
Akt and MAPK (42) are the two major oncogenic
pathways activated by PDGF stimulation, and we
sought to determine their contribution to miR-146b
up-regulation. Therefore we measured the effects of
a MEK (PD98059), PI3K (LY294002) and PDGFR
(imatinib mesylate) inhibitors on miR-146b.
Pre-treatment with these inhibitors prevented miR-146b
induction by PDGF-BB (Figure 3D), suggesting that
both the ERK (inhibited by PD98059) and the AKT
(inhibited by LY294002) signaling pathways are involved
in miR-146b induction.
To generate mechanistic insight into PDGF chains
speciﬁc effects on miR expression, we assessed the differ-
ential impact of PDGF-AA versus PDGF-BB on the
major downstream signaling pathways. In C272/hTert/
E7 cells, PDGF-AA induced phosphorylation of
PDGFRa, but not of PDGFRb within 30min
(Figure 4A). In contrast, PDGF-BB led to phosphoryl-
ation of both receptor subunits and its effects were more
prominent than those of PDGF-AA. Akt was rapidly
phosphorylated after stimulation with each of the two
PDGFs. At equivalent doses of PDGF (25ng/ml),
PDGF-BB induced Akt phosphorylation more promin-
ently compared to PDGF-AA. Likewise, MAPK
p42/p44 was and more rapidly and robustly activated by
PDGF-BB compared to PDGF-AA (Figure 4A), suggest-
ing that the former is a more potent stimulator of this
pathway. An important transcription factor induced by
PDGF is c-Fos (43). In C272HTERT/E7 cells, c-fos
expression was markedly induced by PDGF-BB within
1–3h, but not measurably by PDGF-AA (Figure 4B,
upper and middle panels). As the main mechanism
implicated in c-fos engagement by PDGF is the activation
of MAPK pathway (44), we measured the effects of its
inhibition. The MAPK inhibitor, PD98059, blocked
c-fos induction by PDGF-BB, while LY294002 did not
affect it (Figure 4B, lower panel), indicating that
PDGF-BB engages c-fos more effectively than
PDGF-AA, and does so by activating the MAPK
pathway.
To further understand the relevance of PDGF to the
induction of miR-146b, we performed an in silico search
upstream of the miR-146b sequence for known transcrip-
tion factors activated by PDGF (http://microrna.sanger
.ac.uk/sequences/ftp/genomes/hsa.gff). This led to the
identiﬁcation of a putative binding site for c-fos at
position  2300 upstream of miR-146b (Figure 4D). c-fos
knockdown by siRNA repressed the expression level of
miR-146b induced by PDGF-BB (Figure 4C, P=0.007).
Binding of c-fos to the miR-146b promoter was shown by
ChIP utilizing primers encompassing from  2447 to
 2205 region upstream of the transcription starting site
of miR-146b. c-fos interaction with this miR-146b
promoter region was enhanced by PDGF-BB
(Figure 4D, lower panel), further supporting the signiﬁ-
cance of c-fos to PDGF-BB induced up-regulation of
miR-146b.
MiR-146b modulates the balance between PDGF and
EGF signaling
We next searched for possible targets of miR-146b by
using bioinformatic predictive tools (http://www.diana
.pcbi.upenn.edu/cgi-bin/miRGen/v3/Targets.cgi). Having
learned that in other systems EGFR is a miR-146b
target (45), we tested whether changes in miR-146b expres-
sion alter EGFR expression. Transfection of a commercial
miR-146b mimic led to repression of EGFR protein
expression level (Figure 5A, left panel). Conversely, trans-
fection of a LNA targeting miR-146b caused its knock
down (not shown) and subsequent up-regulation of
EGFR protein expression level (Figure 5A, right panel).
However, as expected, the variation in miR-146b expres-
sion levels resulting from ectopic overexpression or
LNA-mediated knock down of miR-146b achieved in
these experiments exceeded the range of PDGF-BB
induced changes in cancer cells. Therefore, to test
whether by altering miR-146b’s expression, PDGF-BB
Nucleic Acids Research, 2011,Vol.39, No. 10 4041regulates the expression level of EGFR; we measured the
receptor’s expression after PDGF-BB treatment and noted
down-regulation of EGFR protein level 6–24h after
PDGF-BB stimulation (Figure 5B, upper panel). In
contrast, PDGF-AA did not decrease measurably EGFR
expression, in concordance with the known lack of induc-
tion of miR-146b by PDGF-AA (Figure 5B, lower panel).
To investigate whether miR-146b has a signiﬁcant
contribution to the effect of PDGF-BB on EGFR, this
miR was overexpressed and cells were treated with
vehicle or PDGF-BB. Overexpression of miR-146b in
C272hTERT/E7 cells down-regulated EGFR expression
as compared to cells transfected with control miR.
EGFR expression was further suppressed in cells
Figure 3. PDGF BB up-regulates miR-146b. (A) qPCR quantiﬁes miR-146b in U118, U87-MG, C272/hTert/E7 and SH-SY5Y after PDGF-BB
treatment. (B) qPCR quantiﬁes miR-146b in WI38 ﬁbroblasts after PDGF-BB treatment. (C) qPCR quantiﬁes miR-146b in C272/hTert/E7 cells in
response to PDGF-AA, PDGF-BB, VEGF and EGF. (D) qPCR quantiﬁes miR-146b in C272hTert/E7 cells treated with PDGF-BB and PD98059,
LY294002 and imatinib mesylate. RNU49 was used as control for all qPCR reactions.
4042 Nucleic Acids Research, 2011,Vol.39, No. 10overexpressing miR-146b after treatment with PDGF-BB
(Figure 5C, upper panels). To further validate that the
regulation of EGFR is mediated by miR-146b through
binding to its 30-UTR region, we measured the effects of
PDGF-BB on the activity of an EGFR’s 30-UTR-
luciferase reporter. PDGF-BB repressed the reporter
activity of the wild-type 30-UTR fragment (P=0.04;
Figure 5C, lower left panel), but not that of a 30-UTR
fragment lacking the miR-146b seed sequence (P=0.56,
Figure 5C, lower right panel). These data suggest that one
possible mechanism through which PDGF-BB regulates
EGFR expression occurs via modulation of miR-146b ex-
pression levels.
To gain further insight into the functional signiﬁcance
of the effects of PDGF on EGF-EGFR signaling, C272/
hTert/E7 cells that express both PDGFRs and the EGFR,
were stimulated with PDGF-BB and EGF, either alone, in
combination, or in succession. Two doses of PDGF (5 and
25ng/ml) and of EGF (20 and 150ng/ml) were used
(Figure 5D, upper panel). As anticipated, PDGF-BB
phosphorylated the PDGFR-b, but not the EGFR;
while EGF potently phosphorylated the EGFR.
MAPK42/44 activation was induced by PDGF-BB as
well as by EGF at comparable levels, but Akt phosphor-
ylation was more potently induced by PDGF-BB
compared to EGF (Figure 5C, top panel). Interestingly,
pre-stimulation with PDGF-BB for 3h prior to EGF,
attenuated EGFR phosphorylation as compared to
EGF-induced receptor activation (Figure 5D, top panel,
lane 6 versus 4 and 5). This suggested that PDGF-BB may
induce a factor which inhibits the effects of EGF. This
effect was not observed when the two growth factors
Figure 4. Mechanism of miR-146b regulation by PDGF BB. (A) Phosphorylation of PDGFRa and b, Akt and MAPKp42/p44 was measured by
western blotting in C272hTert/E7 cells stimulated with PDGF-AA (25ng/ml) or PDGF-BB (25ng/ml) for 30min to 24h. (B) Western blotting for
c-Fos in C272/hTert/E7 cells treated with PDGF-BB for 2–24h (upper panel). Western blotting for c-Fos in C272/hTert/E7 cells treated with
PDGF-AA for 2–24h (middle panel). Western blotting quantiﬁes c-fos in C272hTert/E7 cells stimulated with PDGF-BB in the presence or not of
PD98059 and LY294002 inhibitors (lower panel). (C) C272Htert/E7 cells were transfected with c-fos targeted siRNA or scrambled siRNA (control)
and treated with PDGF BB. MiR-146b was quantiﬁed by qPCR (P=0.007). Statistical signiﬁcance is marked by asterisks. (D) Schematic repre-
sentation of the c-fos binding site at position  2300 upstream of the miR-146b and the position of primers chosen for ampliﬁcation in the ChIP
assay. ChIP assay tests binding of c-Fos to the miR-146b promoter region after PDGF-BB stimulation. A 242-bp PCR product was detected by gel
agarose electrophoresis from chromatin immunoprecipitated with an antibody against c-fos (lanes 3 and 4) using primers ﬂanking the c-fos binding
region of the miR-146b promoter ( 2447 to  2205bp). Positive controls are amplicons from input chromatin (lanes 1 and 2). Negative controls
consist of chromatin immunoprecipitated with non-speciﬁc IgG and ampliﬁed with primers speciﬁc to the miR-146b promoter (lanes 5 and 6) and
chromatin immunoprecipitated with c-fos antibody and ampliﬁed with primers away from the predicted c-fos binding site (lanes 7 and 8).
Nucleic Acids Research, 2011,Vol.39, No. 10 4043Figure 5. MiR-146b targets the EGFR. (A) Western blotting for EGFR in U118MG cells transfected with miR-146b precursor or control (left) or
with LNA targeting miR-146b or scrambled LNA (right). (B) Western blotting for EGFR in C272/hTert/E7 cells treated with PDGF-BB for 3–24h
(upper panel). Western blotting for EGFR in C272/hTert/E7 cells treated with PDGF-AA for 2–24h (lower panel). (C) Western blotting assessed
EGFR expression in C272/hTERT/E7 cells treated with PDGF-BB for 6h after transfection of miR-146b precursor or control leading to miR-146b
over-expression. Densitometry quantiﬁes EGFR expression levels relative to GAPDH in independent experiments. Statistical signiﬁcance is indicated
by asterisks (upper panels, NS, not signiﬁcant). Reporter assay measured the activity of an EGFR 30-UTR-luciferase construct before and after
stimulation with 50ng/ml of PDGF-BB (lower panels). Reporter activity of wild-type EGFR 30-UTR (left) and mutated 30-UTR (right) were
measured and normalized to renilla activity. Statistical signiﬁcance is marked by asterisks; NS, non-signiﬁcant. (D) Phosphorylation of PDGFRb,
EGFR, Akt and MAPK p42/p44 were measured by western blotting (upper panel) in C272hTert/E7 cells stimulated for 30min with PDGF BB
(5ng/ml, lane 2 and 25ng/ml, lane 3), EGF (20ng/ml, lane 4 and 150ng/ml, lane 5) or a combination of PDGF and EGF (pre-treatment with PDGF
for 3h, followed by EGF; lane 6; or concomitant stimulation with PDGF and EGF for 30min; lane 7). Phosphorylation of EGFR and total
expression of EGFR were measured by Western blotting in C272hTert/E7 cells (lower panel) transfected with LNA targeting miR-146b or control.
Cells were then treated with EGF (20ng/ml, lanes 2 and 5) or with PDGF for 3h prior to stimulation with EGF (lanes 3 and 6). Densitometry
quantiﬁes EGFR phosphorylation and total expression relative to GAPDH. (E) EGFR and miR-146b relative expression plot obtained by using
relative expression data after standardization of EGFR relative expression values and miR-146b. F(x) is the estimated linear trend function.
4044 Nucleic Acids Research, 2011,Vol.39, No. 10were administered simultaneously (Figure 5D, top panel,
lane 7 versus 6). Activation of Akt and MAPK42/44
downstream of the EGFR was not affected by the
sequence of growth factor administration, likely because
of the overlapping effects of PDGF and EGF on these
pathways.
To demonstrate that PDGF-induced inhibition of
EGFR phosphorylation occurred at least in part via
induction of miR-146b, we knocked-down miR-146b
prior to stimulation with EGF or with PDGF followed
by EGF. miR-146b knockdown accentuated EGFR
activation in response to EGF when compared to
control-LNA transfected cells (Figure 5D, lower panel,
lanes 2 and 5) and this occurred in parallel with an
increase in the expression level of EGFR. Further,
miR-146b knockdown prevented partially the attenuation
of EGFR phosphorylation induced by pre-treatment with
PDGF prior to EGF (Figure 5D, lower panel, lanes 3 and
6). These data demonstrate how a miR ﬁne tunes the
cancer cells’ response to different growth signals.
Lastly, to illustrate the functional signiﬁcance of
miR-146b expression to EGFR’s expression in vivo,
we measured by qPCR the expression levels of EGFR
and miR-146b in 19 human glioblastoma specimens.
mir-146b and EGFR expression levels were inversely
correlated (Pearson coefﬁcient  0.38, P=0.05, one tail,
Figure 5E), demonstrating that this miR-receptor inter-
action can still be detected in tumors despite the complex-
ity of in vivo systems.
DISCUSSION
Signiﬁcant literature, including our previous studies,
demonstrates that autocrine PDGFR activation plays a
critical role in cancer progression via regulation of
speciﬁc molecular networks (21,22,24). In the current
study, we provide new evidence that PDGF-initiated
signaling alters the human miRnome, with signiﬁcant
repercussions on target gene expression and function.
This report implicates alterations of ncRNAs in the
effects of PDGF signaling on gene regulation in cancer
cells and demonstrates that distinct PDGF ligands have
speciﬁc effects on miR expression.
The original observations that a signiﬁcant proportion
of miRs exhibit altered expression patterns in tumors, with
or without corresponding genomic alterations, established
the foundation for the ongoing ‘ncRNAs revolution’ in
oncology (34,46). Mechanistically, cancer-associated
miRs directly or indirectly regulate genes with critical
roles in tumor formation, including oncogenes or tumor
supressors (46). Additionally, miRs respond to cytokines,
estrogen, and a variety of stresses, which are relevant to
our understanding of the cancer microenvironment (47),
as well as of other non-malignant disorders or of normal
physiological responses.
The impact of our studies is at least 3-fold. First, the
two PDGF ligands (AA and BB) exhibit compelling dif-
ferences in their impact on miRs expression. Repression of
let-7d is speciﬁcally induced by PDGF-AA, whereas
induction of miR-146b is speciﬁc to PDGF-BB. To our
knowledge, this represents the ﬁrst evidence for PDGF
ligand-speciﬁc miRs response, and may help explain
some of the observed different effects elicited by the two
forms (12,48). PDGFs’ effects on miR expression have
been described in non-transformed mesenchymal cells in
rapport to cell proliferation and migration induced by
these growth factors (49–51). However, miRs previously
described to be inducible by PDGF in smooth muscle cells
(e.g. miR-24, miR-221) were not identiﬁed by the global
approach (miR arrays) utilized in our study. These differ-
ences may be attributable to the cancer phenotype studied
here or to the threshold for detection of differences in gene
expression levels imposed by the use of miR arrays.
Second, transcription factors regulate miR expression in
a fashion similar to the regulation of classic genes, well
documented examples including HIF-miR-210 (47) and
p53-miR-34a (52). Here we show that PDGF induces
miR-146b through a c-fos dependent mechanism. These
ﬁndings expand the accepted classical pathway of gene
expression modulated by PDGF through recruitment of
factors that activate gene transcription to include a new
mechanism dependent on ncRNAs. This model may help
to improve our understanding of how different down-
stream responses are derived from relatively similar
upstream growth factors.
Third, EGFR expression is regulated by miR-146b in
response to PDGF-BB. While miR-146b has been shown
to target EGFR (45), we provide evidence for a feedback
mechanism stemming from PDGFR signaling, potentially
providing proof of principle for a shift between growth
factor signaling in cancer cells. We also demonstrate
that the EGFR and miR-146b expression are inversely
correlated in vivo. These ﬁndings suggest that ncRNAs
participate in the ﬁne tuning of cellular responses to
external stimuli, balancing one growth factor pathway
versus another. Given that the two growth factors’
effects on cell proliferation and survival are to some
extent redundant, this mechanism may explain how cells
adapt to stimuli from the micro-environment by turning
off un-necessary growth or survival pathways. It is also
possible that the ncRNA-modulated shift between
response to PDGF (a mesenchymal factor) and EGF
(an epithelial factor) may have implications for maintain-
ing the balance between epithelial and mesenchymal
features of cancer cells, and perhaps inﬂuence the transi-
tion between the two states. For this study, we dissected
this mechanism in the context of cancer cells, however we
do not exclude the possibility that a similar feedback loop
may operate in non-transformed cells during physiologic
responses.
The above ﬁndings also point to potential clinical ap-
plications of this regulatory mechanism. When PDGF sig-
naling is turned off by inhibitors, PDGF inducible miRs
may be silenced and subsequently their targets, including
the alternative growth pathway (e.g. EGF-EGFR), may
become de-repressed. If operative in tumors in vivo, this
link may contribute to resistance to PDGFR inhibitors.
Understanding this mechanism may help to develop
strategies that take into account the interconnected
arrays of growth factors in the tumor environment.
Nucleic Acids Research, 2011,Vol.39, No. 10 4045In summary, our ﬁndings expand the classical view
of PDGF-initiated signaling and provide insight into
the regulation of known and/or new targets of PDGF.
The involvement of PDGF-inducible ncRNAs may
explain differences between biological effects of speciﬁc
PDGF ligands and feedback regulatory mechanisms
between growth pathways in cancer cells. These ﬁndings
have implications for development of therapies targeting
the PDGFR in cancer.
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